Compare Regeneron Pharmaceuticals Inc (REGN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Under Armour Inc Class A trades at $7.08 (market cap $3.11B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 22.8× Under Armour Inc Class A's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| REGN | UA | |
|---|---|---|
Market Cap | $70.79B | $3.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $7.88 |
52-Week Low | $545.46 | $3.96 |
Enterprise Value | $64.74B | $4.74B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $201.27 million in fiscal 2025, with negative margins and cash flow, though revenue remains substantial at $5.16 billion. Recent news highlights a new Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
Outlook is mixed: analyst consensus leans slightly bullish with 40% buy ratings, but fundamental challenges persist including declining revenue projections and negative profitability. Key risks include execution of the business reset and competitive pressures. The stock presents a turnaround opportunity but requires careful monitoring of earnings and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
